ZURA Zura Bio Limited
Zura Bio Limited (ZURA) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.3% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Zura Bio Limited
Zura Bio Limited is a clinical-stage biotechnology company advancing primary assets, including ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease and asthma. Zura Bio Limited, formerly known as JATT Acquisition Corp, is headquartered in London, UK.
Sector
Healthcare
Industry
Biotechnology